Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.

@article{Puvvada2018Phase2O,
  title={Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.},
  author={Soham D Puvvada and Jos{\'e} M Guill{\'e}n-Rodr{\'i}guez and Abhijeet Kumar and Lora Incl{\'a}n and Kara Heard and Xavier Issac Rivera and Faiz Anwer and Jonathan H Schatz and Daruka Mahadevan and Daniel O Persky},
  journal={Clinical lymphoma, myeloma & leukemia},
  year={2018},
  volume={18 1},
  pages={
          58-64
        }
}
BACKGROUND Mantle-cell lymphoma (MCL) and indolent non-Hodgkin lymphoma (iNHL) are incurable heterogeneous diseases characterized by relapse. There is a need for newer treatments in MCL and iNHL, especially in the relapsed/refractory (R/R) setting. We therefore investigated the novel combination of bortezomib (Velcade), cladribine, and rituximab (VCR) in front-line and R/R settings in MCL and iNHL (NCT00980395). PATIENTS AND METHODS Eligible patients included adults with biopsy-proven CD20… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

  • A Noy
  • Am Soc Hematology,Abstract
  • 2016
Highly Influential
5 Excerpts

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

  • Wang, M.L
  • 2015
Highly Influential
5 Excerpts

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

  • Flinn, I.W
  • 2014
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…